484 related articles for article (PubMed ID: 33789273)
21. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
Subbarao K; Mordant F; Rudraraju R
Eur J Immunol; 2020 Oct; 50(10):1447-1453. PubMed ID: 32886952
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.
Karbiener M; Farcet MR; Ilk R; Schreiner J; Lenart J; Powers N; Stewart JM; Tallman H; Kreil TR
Transfusion; 2021 Apr; 61(4):1141-1147. PubMed ID: 33615484
[TBL] [Abstract][Full Text] [Related]
23. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
24. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969
[TBL] [Abstract][Full Text] [Related]
25. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
26. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.
Zeng QL; Yu ZJ; Gou JJ; Li GM; Ma SH; Zhang GF; Xu JH; Lin WB; Cui GL; Zhang MM; Li C; Wang ZS; Zhang ZH; Liu ZS
J Infect Dis; 2020 Jun; 222(1):38-43. PubMed ID: 32348485
[TBL] [Abstract][Full Text] [Related]
27. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
Garraud O
Transfus Apher Sci; 2020 Aug; 59(4):102858. PubMed ID: 32631501
[No Abstract] [Full Text] [Related]
28. COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.
Bansal N; Raturi M; Bansal Y
Transfus Clin Biol; 2021 Aug; 28(3):308-309. PubMed ID: 33971319
[TBL] [Abstract][Full Text] [Related]
29. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
31. COVID-19: benefits and risks of passive immunotherapeutics.
Gupta A; Karki R; Dandu HR; Dhama K; Bhatt ML; Saxena SK
Hum Vaccin Immunother; 2020 Dec; 16(12):2963-2972. PubMed ID: 32962524
[TBL] [Abstract][Full Text] [Related]
32. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.
Natarajan H; Crowley AR; Butler SE; Xu S; Weiner JA; Bloch EM; Littlefield K; Wieland-Alter W; Connor RI; Wright PF; Benner SE; Bonny TS; Laeyendecker O; Sullivan D; Shoham S; Quinn TC; Larman HB; Casadevall A; Pekosz A; Redd AD; Tobian AAR; Ackerman ME
mBio; 2021 Apr; 12(2):. PubMed ID: 33879585
[TBL] [Abstract][Full Text] [Related]
33. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
Lindholm PF; Ramsey G; Kwaan HC
Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 Vaccine: A comprehensive status report.
Kaur SP; Gupta V
Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
[TBL] [Abstract][Full Text] [Related]
35. Convalescent serum lines up as first-choice treatment for coronavirus.
Sheridan C
Nat Biotechnol; 2020 Jun; 38(6):655-658. PubMed ID: 32358594
[No Abstract] [Full Text] [Related]
36. Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.
Brox R; Achenbach S; Hackstein H
Transfusion; 2021 Nov; 61(11):3087-3093. PubMed ID: 34546583
[TBL] [Abstract][Full Text] [Related]
37. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.
Iftikhar A; Jabeen F; Manzoor M; Younis T; Shaheen M
Acta Microbiol Immunol Hung; 2020 Jul; 67(2):87-90. PubMed ID: 32619190
[TBL] [Abstract][Full Text] [Related]
38. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
39. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.
De Silvestro G; Gandini G; Fiorin F; Marson P; Barbone E; Frigato A; Gessoni G; Veronesi A; Pacenti M; Castelli M; Rinaldi M; Rizzi M; Stefani F; Roveroni G
Transfus Apher Sci; 2021 Aug; 60(4):103154. PubMed ID: 33994107
[TBL] [Abstract][Full Text] [Related]
40. Convalescent Plasma Therapy for COVID-19: State of the Art.
Focosi D; Anderson AO; Tang JW; Tuccori M
Clin Microbiol Rev; 2020 Sep; 33(4):. PubMed ID: 32792417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]